EGFR and hepatocellular carcinoma: In conclusion, the current study provides evidence that STARD4 promotes the proliferation, metastasis, and lenvatinib resistance of HCC by modulating cholesterol homeostasis and subsequently activating the EGFR/PI3K/AKT pathway.